These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 26732066)

  • 1. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
    Watanabe T; Tobinai K; Matsumoto M; Suzuki K; Sunami K; Ishida T; Ando K; Chou T; Ozaki S; Taniwaki M; Uike N; Shibayama H; Hatake K; Izutsu K; Ishikawa T; Shumiya Y; Kashihara T; Iida S
    Br J Haematol; 2016 Mar; 172(5):745-56. PubMed ID: 26732066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).
    Abe Y; Kubonishi S; Ri M; Iino M; Sunami K; Ito T; Fukaya M; Kitano T; Ikeda S; Ota S; Kuroi T; Iriyama N; Jo T; Adachi M; Akahane D; Kai T; Kohara Y; Kadowaki N; Katayama T
    Future Oncol; 2024; 20(17):1191-1205. PubMed ID: 38420911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
    Berdeja JG; Hart LL; Mace JR; Arrowsmith ER; Essell JH; Owera RS; Hainsworth JD; Flinn IW
    Haematologica; 2015 May; 100(5):670-6. PubMed ID: 25710456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib: a novel second-generation proteasome inhibitor.
    Khan ML; Stewart AK
    Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
    Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
    Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.
    Fakhri B; Fiala MA; Shah N; Vij R; Wildes TM
    Cancer; 2020 Feb; 126(4):808-813. PubMed ID: 31721140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma.
    Shabnaz S; Nguyen TN; Williams R; Rubinstein SM; Garrett TJ; Tantawy M; Fradley MG; Alomar ME; Shain KH; Baz RC; Lenihan D; Cornell RF; Lu Q; Gong Y
    Clin Transl Sci; 2024 May; 17(5):e13828. PubMed ID: 38783568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib.
    Maruhashi T; Miki H; Sogabe K; Oda A; Sumitani R; Oura M; Takahashi M; Harada T; Fujii S; Nakamura S; Kurahashi K; Endo I; Abe M
    Int J Hematol; 2024 Mar; 119(3):291-302. PubMed ID: 38252236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted treatments for multiple myeloma: specific role of carfilzomib.
    Sugumar D; Keller J; Vij R
    Pharmgenomics Pers Med; 2015; 8():23-33. PubMed ID: 25691814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect.
    Sridhar A; Yohannan B; Kachira JJ; Bhama S
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35787495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib use in patients with relapsed/refractory multiple myeloma in France: A national retrospective cohort study.
    Hulin C; Quignot N; Jiang H; Mechiche H; Désaméricq G
    EJHaem; 2024 Aug; 5(4):887-891. PubMed ID: 39157605
    [No Abstract]   [Full Text] [Related]  

  • 12. Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.
    Raedler LA
    Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):93-6. PubMed ID: 27668053
    [No Abstract]   [Full Text] [Related]  

  • 13. Carfilzomib and Proteinuria: Potential Interference or Iatrogeny?
    Vaudran L; Loiseleur F; Nezry N; Courtin J; Schraen S; Onraed B
    J Appl Lab Med; 2024 Sep; 9(5):1074-1076. PubMed ID: 38809716
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Tobinai K; Taniwaki M; Shumiya Y; Nakamura T; Chou T
    Int J Hematol; 2016 Nov; 104(5):596-604. PubMed ID: 27460677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Myeloma: Diagnosis and Treatment.
    Rajkumar SV; Kumar S
    Mayo Clin Proc; 2016 Jan; 91(1):101-19. PubMed ID: 26763514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
    Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
    Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
    N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
    Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
    N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
    Hájek R; Masszi T; Petrucci MT; Palumbo A; Rosiñol L; Nagler A; Yong KL; Oriol A; Minarik J; Pour L; Dimopoulos MA; Maisnar V; Rossi D; Kasparu H; Van Droogenbroeck J; Yehuda DB; Hardan I; Jenner M; Calbecka M; Dávid M; de la Rubia J; Drach J; Gasztonyi Z; Górnik S; Leleu X; Munder M; Offidani M; Zojer N; Rajangam K; Chang YL; San-Miguel JF; Ludwig H
    Leukemia; 2017 Jan; 31(1):107-114. PubMed ID: 27416912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
    Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
    Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.